The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy

Ophthalmology

Volumn 118, Issue 11, 2011, Pages 2218-2226

  Ahn, Jeeyun ^a,b   Woo, Se Joon ^a,b   Chung, Hum ^a,c   Park, Kyu Hyung ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; ENDOPHTHALMITIS; FEMALE; HEART INFARCTION; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA DETACHMENT; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOTHERAPY, ADJUVANT; DIABETIC RETINOPATHY; FEMALE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 80255124891     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.03.036     Document Type: Article

References (31)

1. A.P. Schachat, R.T. Oyakawa, R.G. Michels, and T.A. Rice Complications of vitreous surgery for diabetic retinopathy II. Postoperative complications Ophthalmology 90 1983 522 530
2. R.F. Spaide, and Y.L. Fisher Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina 26 2006 275 278
3. R.L. Avery, J. Pearlman, and D.J. Pieramici Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 2006 1695 1705
4. J.O. Mason III, P.A. Nixon, and M.F. White Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy Am J Ophthalmol 142 2006 685 688
5. S. Rizzo, F. Genovesi-Ebert, and E. Di Bartolo Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR) Graefes Arch Clin Exp Ophthalmol 246 2008 837 842
6. H. Ahmadieh, N. Shoeibi, M. Entezari, and R. Monshizadeh Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial Ophthalmology 116 2009 1943 1948
7. J.F. Arevalo, L. Wu, and J.G. Sanchez Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up Eye (Lond) 23 2009 117 123
8. D. da R Lucena, J.A. Ribeiro, and R.A. Costa Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study) Br J Ophthalmol 93 2009 688 691
9. M.R. Romano, S.K. Gibran, and J. Marticorena Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye (Lond) 23 2009 1698 1701
10. L. Yeung, L. Liu, and W.C. Wu Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment Acta Ophthalmol 88 2010 635 640
11. R. di Lauro, P. De Ruggiero, and R. di Lauro Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy Graefes Arch Clin Exp Ophthalmol 248 2010 785 791
12. M.R. Romano, S.K. Gibran, and J. Marticorena Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage? Eur J Ophthalmol 19 2009 618 621
13. R.A. Cheema, J. Mushtaq, and W. Al-Khars Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage Retina 30 2010 1646 1650
14. D.H. Park, J.P. Shin, and S.Y. Kim Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study Graefes Arch Clin Exp Ophthalmol 248 2010 641 650
15. C. Eckardt Transconjunctival sutureless 23-gauge vitrectomy Retina 25 2005 208 211
16. S.J. Woo, K.H. Park, and J.M. Hwang Risk factors associated with sclerotomy leakage and postoperative hypotony after 23-gauge transconjunctival sutureless vitrectomy Retina 29 2009 456 463
17. L.P. Aiello, A.J. Brucker, and S. Chang Evolving guidelines for intravitreous injections Retina 24 2004 S3 S19
18. A.P. Adamis, J.W. Miller, and M.T. Bernal Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 1994 445 450
19. L.P. Aiello, R.L. Avery, and P.G. Arrigg Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480 1487
20. W.R. Lo, S.J. Kim, and T.M. Aaberg Sr Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (Avastin) Retina 29 2009 926 931
21. T.U. Krohne, N. Eter, F.G. Holz, and C.H. Meyer Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am J Ophthalmol 146 2008 508 512
22. H.S. Chin, T.S. Park, Y.S. Moon, and J.H. Oh Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes Retina 25 2005 556 560
23. E. Stefansson Physiology of vitreous surgery Graefes Arch Clin Exp Ophthalmol 247 2009 147 163
24. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 2008 579 591
25. S. Honda, H. Hirabayashi, Y. Tsukahara, and A. Negi Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity Graefes Arch Clin Exp Ophthalmol 246 2008 1061 1063
26. J.F. Arevalo, M. Maia, and H.W. Flynn Jr Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy Br J Ophthalmol 92 2008 213 216
27. Y. Oshima, C. Shima, and T. Wakabayashi Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment Ophthalmology 116 2009 927 938
28. J.O. Mason III, M.F. White, and R.M. Feist Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection Retina 28 2008 564 567
29. L. Wu, M.A. Martinez-Castellanos, H. Quiroz-Mercado Pan American Collaborative Retina Group (PACORES) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 2008 81 87
30. S.H. Lee, S.J. Woo, and K.H. Park Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab Eye (Lond) 24 2010 226 232
31. C.M. Yang, P.T. Yeh, and C.H. Yang Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy Ophthalmology 114 2007 710 715